Longitudinal changes in high molecular weight serum adiponectin levels in healthy infants
Related Experiment Video
Updated: Jun 27, 2026
Isolation, Expansion, and Adipogenic Induction of CD34+CD31+ Endothelial Cells from Human Omental and Subcutaneous Adipose Tissue
Published on: July 17, 2018
Satoshi Hibino1, Kazuo Itabashi, Yuya Nakano
1Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8666, Japan.
Insights
High molecular weight adiponectin (HMW-ad) levels in infants decrease significantly by 12 months. Cord blood HMW-ad levels predict infant levels, suggesting prenatal regulation.
Area of Science:
- Pediatrics
- Endocrinology
- Metabolic Health
Background:
- Adiponectin, particularly high molecular weight adiponectin (HMW-ad), plays a crucial role in metabolic regulation.
- Understanding the factors influencing HMW-ad levels in early life is essential for predicting long-term metabolic health.
- Longitudinal data on HMW-ad during infancy is limited.
Purpose of the Study:
- To investigate the longitudinal changes in serum HMW-ad levels from birth to 12 months of age in healthy infants.
- To identify factors associated with HMW-ad levels during the first year of life.
Main Methods:
- A longitudinal study measuring total adiponectin, HMW-ad, and leptin in 56 healthy infants from birth to 12 months.
- Serum samples were collected at birth, 6 months, and 12 months.
- Multiple regression analysis was used to determine predictive factors for HMW-ad levels.
Main Results:
- Serum HMW-ad levels showed a strong positive correlation with total adiponectin levels (R2 = 0.93).
- HMW-ad levels at 12 months (7.7 ± 0.5 μg/mL) were significantly lower than at birth (13.7 ± 0.9 μg/mL) and 6 months (13.3 ± 0.8 μg/mL).
- Multiple regression analysis indicated that only cord blood HMW-ad levels significantly predicted HMW-ad levels at 12 months (β = 0.680).
Conclusions:
- Postnatal HMW-ad production during infancy may be regulated prenatally.
- Cord blood HMW-ad levels are a key determinant of HMW-ad levels in the first year of life.
- Further research is needed to explore the role of cord blood HMW-ad in metabolic syndrome development.
Abstract:
To determine the factors associated with high molecular weight adiponectin (HMW-ad) levels during the first year of life, the longitudinal changes in serum HMW-ad were investigated from birth to 12 mo of age. The total adiponectin levels, HMW-ad, and leptin were measured longitudinally from birth to 12 mo of age in 56 healthy infants (>or=35 wk of gestation). Serum HMW-ad levels were positively correlated with total adiponectin levels (R2 = 0.93, p < 0.0001). Serum HMW-ad levels at birth, six, and 12 mo were 13.7 +/- 0.9 (mean +/- SE), 13.3 +/- 0.8, and 7.7 +/- 0.5 microg/mL, respectively. The levels at 12 mo were significantly lower than those at birth and 6 mo, respectively. In a multiple regression analysis, the HMW-ad levels at 12 mo were found to be related only to cord blood HMW-ad levels (beta = 0.680, p < 0.001) and not to any other factors. These results imply that postnatal production of HMW-ad at least during infancy may be regulated before birth. Further study is necessary to determine whether cord blood HMW-ad has an effect and whether it is involved in the development of metabolic syndrome.
